Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C38717
http://purl.obolibrary.org/obo/NCIT_C38717
Preferred Name

Anakinra
Definitions
A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)
prefLabel
Anakinra
label
Anakinra
PDQ_Closed_Trial_Search_ID
43007
code
C38717
Has_Target
prefixIRI
NCIT:C38717
in_subset
Display_Name
Anakinra
Preferred_Name
Anakinra
FDA_UNII_Code
9013DUQ28K
Contributing_Source
CTRP
FDA
Maps_To
Anakinra
CAS_Registry
143090-92-0
NCI_Drug_Dictionary_ID
43007
Legacy Concept Name
Anakinra
type
ALT_DEFINITION
A substance that is used to treat rheumatoid arthritis, and is being studied in the treatment of cancer. Anakinra blocks the action of interleukin 1 (IL-1). It is a type of interleukin receptor antagonist.
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
43007
Accepted_Therapeutic_Use_For
Rheumatoid arthritis
Is_Related_To_Endogenous_Product
Semantic_Type
Pharmacologic Substance
UMLS_CUI
C0245109
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display